Gland Pharma Ltd (GLAND) is currently trading at 2,883.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems. The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France. Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline. The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream. Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.

Over the past 52 weeks, Gland Pharma Ltd has traded between a low of ₹1,575.00 and a high of ₹3,041.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gland Pharma Ltd has a market capitalization of approximately 48,214.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gland Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.71 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 48,214.81 Cr, Gland Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gland Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 42.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Fosun Pharma said its Singapore unit sold 9.897 million shares (98.97 lakh), representing about 6% of Gland Pharma’s share capital as of September 3, 2026.

Gland Pharma said the deal has annualised revenue potential of USD 90–100 million once all products are commercialised.

Gland Pharma’s 48th AGM is scheduled for Tuesday, August 25, 2026 at 11:00 A.M. IST.

USFDA approved Gland Pharma’s ANDA for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL (100 mg/mL) single-dose vials.